South San Francisco, Calif.
Went public 5/2/2000 at $7 a piece
Filing Range: 5 mil. shares @ $7 to $8
Shares Outstanding: 19.68 mil. shares
Underwriters: CIBC World Markets
ING Barings/Prudential Vector Healthcare
Company Counsel: Cooley Godward LLP
Manager Counsel: McDermott Will & Emery
Auditor: Ernst & Young LLP
The Company:
The company has developed a method of directly measuring the impact of genetic mutations on drug resistance and uses this information to guide therapy.
Venture Backers:
Biotech Growth S.A.
Zesiger Capital Group
Capital Management Services Inc.
Invemed Associates Inc.
Financing Rounds
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 09/01/1998 1 Expansion $100.0
FINANCIALS
(Data in $ millions)
Y/E
12/31/99
Total Revenues: $1.1
Net Loss: -17.1